How GLP-1 Medications Are Changing Consumer Behavior – Harvard Business Review
While blockbuster drug innovations have changed health outcomes for decades, we’re now seeing signs that GLP-1 medications like Ozempic and Wegovy may be changing something broader: the consumer economy. Originally developed for diabetes and increasingly prescribed for weight loss, these drugs are not just influencing physical health and body size. They’re also reshaping collective behavior—how people eat, shop, move, perceive themselves, and make decisions—with significant implications for business leaders.
Harvard Business Publishing:
Copyright ©2025 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.
source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.
